Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost

ReCode Therapeutics, on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the round’s total to $260m. This will support clinical trials for RCT1100 in primary ciliary dyskinesia and RCT2100 in cystic fibrosis while allowing the company to continue expanding its pipeline of precisely delivered mRNA and gene correction therapeutics.

Menlo Park, CA-based ReCode anticipated when it added $120m to its series B round in June 2022, bringing the round’s total to $200m, that RCT1100 and RCT2100 would enter the...